> Sanofi-Aventis has filed an NDA for rimonabant, which it believes can provide a comprehensive therapy for cardiovascular risks. Release
> Chutes & Ladders: Speeding its transition plans, Canada's MDS says that Stephen DeFalco will become CEO on July 1. Story
> Belgium's Solvay is making a friendly bid to acquire 51 percent of Girindus. Article
> AstraZeneca has presented new data for Zomig showing a 58.1 percent headache response rate among adolescents compared to 43.3 percent for patients taking a placebo. Release
> SciClone Pharmaceuticals of San Mateo, California, has submitted an IND for SCV-07, a synthetic dipeptide that has demonstrated activity against a broad range of viral and infectious diseases. Release
> RegeneRx Biopharmaceuticals of Bethesda, Maryland, has announced a $5 million equity investment. Release
> The European Medicines Agency has given orphan drug status to Nabi Biopharmaceuticals' Civacir for hepatitis C. Release
> Dynavax Technologies of Berkeley, California, has begun a Phase III trial of its hepatitis B vaccine. Release
And Finally... Once thought useless, researchers now say that chemotherapy can play a big role in prolonging the lives of lung cancer victims. Article